Recent progress in the treatment of infant acute lymphoblastic leukemia

Area of Science:

• Pediatric Oncology
• Hematology
• Molecular Biology

Background:

• Infant acute lymphoblastic leukemia (ALL), particularly the mixed lineage leukemia rearrangement (MLL-r) subtype, presents a significant therapeutic challenge.
• MLL-r ALL accounts for approximately 80% of infant ALL cases, with current intensive chemotherapy and stem cell transplantation rescuing only about half of patients.

Purpose of the Study:

• To highlight the urgent need for novel targeted therapies for MLL-r ALL.
• To underscore the importance of understanding the unique molecular mechanisms driving MLL-r ALL.

Main Methods:

• Review of current treatment strategies and outcomes for MLL-r ALL.
• Analysis of recent research elucidating the molecular pathogenesis of MLL-r ALL, focusing on aberrant methylation and histone modifications.
• Description of international collaborative efforts to address the rarity of the disease.

Main Results:

• The study identifies aberrant methylation and histone modifications mediated by MLL fusion proteins and DOT1L as key leukemogenic drivers.
• Current treatment regimens achieve limited success, emphasizing the need for innovative therapeutic approaches.

Conclusions:

• Understanding the specific molecular biology of MLL-r ALL is crucial for developing effective targeted therapies.
• International collaboration among pediatric leukemia study groups is essential to overcome the challenges posed by this rare disease and advance treatment outcomes.